Neuroprotective Effects of Tongmai Yizhi Decoction against Alzheimer's Disease through Attenuating Cyclin-Dependent Kinase-5 Expression

被引:5
作者
Feng Jing-han [1 ]
Cai Bao-chang [2 ]
Guo Wei-feng [1 ]
Wang Ming-yan [3 ]
Ma Yong [1 ]
Lu Qiao-xi [1 ]
机构
[1] Nanjing Univ Chinese Med, Clin Med Coll 1, Nanjing 210023, Jiangsu, Peoples R China
[2] Nanjing Univ Chinese Med, Coll Pharm, Nanjing 210023, Jiangsu, Peoples R China
[3] Nanjing Univ Chinese Med, Basic Med Coll, Nanjing 210023, Jiangsu, Peoples R China
关键词
Alzheimer's disease; cyclin-dependent kinase-5; Tongmai Yizhi Decoction; Chinese medicine; HUPERZINE; CDK5;
D O I
10.1007/s11655-016-2507-0
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objectives: To explore the protective effects of Tongmai Yizhi Decoction (TYD), a Chinese herb complex prescription against the impairment of cognitive functions and memory loss in amyloid beta 1-40 (A beta(1-40)) peptide and ibotenic (IBO)-induced Alzheimer's disease (AD) model rats. Methods: The in vivo model was established by injecting A beta(1-40) and IBO into left hippocampal CA1 area of Sprague-Dawley (SD) rat to mimic AD. Totally 32 SD rats were divided into 4 groups, including sham operation group, AD model group, TYD group [AD rats treated with TYD at the dosage of 19.44 g/(kg.d) for 4 weeks] and huperzine A group [AD rats treated with huperzine A at the dosage of 40.5 mu g/(kg.d) for 4 weeks]. Spatial learning and memory level was detected by Morris Water Maze test. Histological morphology in the hippocampus was tested by hematoxylin-eosin (HE) staining. Cyclin-dependent kinase-5 (Cdk5) protein and gene expression level were investigated by Western blot analysis and real-time quantitative polymerase chain reaction (RT-qPCR), respectively. Results: A beta(1-40) and IBO treatment induced longer escape latency of rats, compared with sham operation group from day 25 (P<0.01). However, TYD and huperzine A obviously shortened the escape latency from day 26 (P < 0.01). Moreover, the effect of TYD was similar to huperzine A (P > 0.05). Furthermore, HE staining also showed that TYD and huperzine A reversed the neuropathological changes in the hippocampus triggered by A beta(1-40) and IBO. TYD and huperzine A effectively reduced the expression levels of Cdk5 protein and gene located in rat hippocampus, compared with the AD model group (P<0.01). Conclusion: TYD could be a promising neuroprotective agent for protecting neuron from AD injury through inhibiting Cdk5 expression.
引用
收藏
页码:132 / 137
页数:6
相关论文
共 36 条
  • [11] Cyclin-dependent kinase-5 prevents neuronal apoptosis through ERK-mediated upregulation of Bcl-2
    C X Wang
    J H Song
    D K Song
    V W Yong
    A Shuaib
    C Hao
    Cell Death & Differentiation, 2006, 13 : 1203 - 1212
  • [12] Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer's disease
    Shukla, Rohit
    Singh, Tiratha Raj
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2020, 38 (01) : 248 - 262
  • [13] Cyclin-dependent kinase-5 prevents neuronal apoptosis through ERK-mediated upregulation of Bcl-2
    Wang, C. X.
    Song, J. H.
    Song, D. K.
    Yong, V. W.
    Shuaib, A.
    Hao, C.
    CELL DEATH AND DIFFERENTIATION, 2006, 13 (07) : 1203 - 1212
  • [14] Cyclin-dependent kinase 5 is associated with risk for Alzheimer's diseasein a Dutch population-based study
    Arias-Vasquez, Alejandro
    Aulchenko, Yurii S.
    Isaacs, Aaron
    van Oosterhout, Andy
    Sleegers, Kristel
    Hofman, Albert
    van Broeckhoven, Christine
    Oostra, Ben A.
    Breteler, Monique
    van Duijn, Cornelia M.
    JOURNAL OF NEUROLOGY, 2008, 255 (05) : 655 - 662
  • [15] A novel approach to cyclin-dependent kinase 5/p25 inhibitors: A potential treatment for Alzheimer's disease
    Shiradkar, Mahendra Ramesh
    Padhalingappa, Mallikarjuna Bandrehally
    Bhetalabhotala, Sastry
    Akula, Kalyan Chakravarthy
    Tupe, Dattu Anna
    Pinninti, Raghotham Reddy
    Thummanagoti, Suman
    BIOORGANIC & MEDICINAL CHEMISTRY, 2007, 15 (19) : 6397 - 6406
  • [16] Cyclin-Dependent Kinase 5 Regulates cPLA2 Activity and Neuroinflammation in Parkinson's Disease
    Paul, Sangita
    Fatihi, Saman
    Sharma, Srishti
    Kutum, Rintu
    Fields, Raymond
    Pant, Harish C.
    Thukral, Lipi
    Binukumar, B. K.
    ENEURO, 2022, 9 (06)
  • [17] Cyclin-Dependent Kinase 5 Activator p25 Is Generated During Memory Formation and Is Reduced at an Early Stage in Alzheimer's Disease
    Engmann, Olivia
    Hortobagyi, Tibor
    Thompson, Andrew J.
    Guadagno, Jennifer
    Troakes, Claire
    Soriano, Salvador
    Al-Sarraj, Safa
    Kim, Yong
    Giese, Karl Peter
    BIOLOGICAL PSYCHIATRY, 2011, 70 (02) : 159 - 168
  • [18] Neuron-specific phosphorylation of Alzheimer's β-amyloid precursor protein by cyclin-dependent kinase 5
    Iijima, K
    Ando, K
    Takeda, S
    Satoh, Y
    Seki, T
    Itohara, S
    Greengard, P
    Kirino, Y
    Nairn, AC
    Suzuki, T
    JOURNAL OF NEUROCHEMISTRY, 2000, 75 (03) : 1085 - 1091
  • [19] RETRACTED ARTICLE: Neuroprotective effect of Buyang Huanwu Decoction on spinal ischemia-reperfusion injury in rats is linked with inhibition of cyclin-dependent kinase 5
    Lei Wang
    Dian-Ming Jiang
    BMC Complementary Medicine and Therapies, 13
  • [20] Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease
    Helal, CJ
    Sanner, MA
    Cooper, CB
    Gant, T
    Adam, M
    Lucas, JC
    Kang, ZJ
    Kupchinsky, S
    Ahlijanian, MK
    Tate, B
    Menniti, FS
    Kelly, K
    Peterson, M
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (22) : 5521 - 5525